News
Mediplus announces release of new sizes of POPY product range
Mediplus has announced the release of new sizes of the POPY (Pelvic Organ Prolapse pessary) product range.
The company is introducing five additional sizes to complement its existing products, offering a more precise fit and enhanced treatment options for women suffering from pelvic organ prolapse.
The POPY pessary range has been expanded to better meet the diverse needs of women with pelvic organ prolapse (POP).
Recognising that one size does not fit all, the range now offers 11 sizes in both short and long stem versions, ensuring a more tailored and effective solution for a wider range of patients.
This expansion provides improved support and comfort, offering a practical and personalised approach to managing POP.
Emma Gray, Managing Director at Mediplus, said: “We are always striving to develop and improve our products in response to the needs of patients and clinicians alike.
“The addition of 5 new sizes to the POPY™ pessary range ensures a better fit for more women, allowing us to provide a more effective, comfortable, and tailored solution for managing pelvic organ prolapse.
“It is part of our ongoing commitment to innovation and patient-centric care.”
Manufactured in the UK, the POPY pessary has long been a trusted, pioneering product in the management of pelvic organ prolapse and procidentia.
Known as the world’s first silicone shelf pessary, it provides a conservative and cost-effective alternative to surgery by alleviating the symptoms of prolapse, offering a comfortable and non-invasive solution that improves patients’ quality of life.
The new sizes reflect Mediplus’ commitment to putting patients first and responding to clinician feedback to ensure that more women can benefit from this innovative solution.
Established in 1986, Mediplus is a family-owned business renowned for its dedication to quality and innovation.
The company’s products have earned two Queens Awards and multiple accolades for contributions to Critical Care and Pelvic Floor, and Urology. Mediplus’s devices are sold in over 40 countries worldwide.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Fertility4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






